qPCR analysis found STAT3 and NF-κB inhibitors significantly repressed RAGE levels in CML and CEL treated cells, while these inhibitors did not completely block the CML/CEL-induced upregulation of RAGE (Figure 3C, D), and the flow cytometry of the cell stain with the anti-RAGE antibody conjugated with FITC also showed the similar results (Figure 3E, F), suggesting the existence of an NF-κB/STAT3-independent mechanism underlying CML/CEL’s effect. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.